Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Aytu BioPharma adds fourth patent license for AR101/Enzastaurin » 08:13
09/14/22
09/14
08:13
09/14/22
08:13
AYTU

Aytu BioPharma

/

+

Aytu BioPharma announced…

Aytu BioPharma announced the addition of a fourth patent to the intellectual property suite surrounding AR101/Enzastaurin. This fourth patent, also licensed from Johns Hopkins University, is titled "Pathway Targets for the Treatment of Vascular Ehlers-Danlos Syndrome," expands the scientific evidence of the pathophysiology of Vascular Ehlers-Danlos Syndrome and is highly confirmatory of the therapeutic approach for AR101/Enzastaurin. The patent has an expiry date of September 2041, assuming no patent term extensions."We're excited about the continued evidence being generated in support of AR101/Enzastaurin for the treatment of VEDS," remarked Josh Disbrow, Chief Executive Officer of Aytu BioPharma. "Adding this fourth patent to the portfolio deepens and broadens the intellectual property surrounding AR101/Enzastaurin for the treatment of inherited vascular disorders, including VEDS, for which we are advancing AR101 as an initial indication. We expect to advance the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023."

ShowHide Related Items >><<
AYTU Aytu BioPharma
/

+

AYTU Aytu BioPharma
/

+

07/21/22 H.C. Wainwright
Aytu BioPharma price target lowered to $6 from $11 at H.C. Wainwright
05/17/22 Cantor Fitzgerald
Aytu BioPharma price target lowered to $5 from $11 at Cantor Fitzgerald
04/28/22 H.C. Wainwright
Aytu BioScience price target lowered to $11 from $24 at H.C. Wainwright
  • 09
    Aug
Over a month ago
Hot Stocks
Aytu BioPharma issued first patent for AR101/Enzastaurin » 08:18
08/16/22
08/16
08:18
08/16/22
08:18
AYTU

Aytu BioPharma

/

+

Aytu BioPharma announced…

Aytu BioPharma announced that the U.S. Patent and Trademark Office has issued a new patent, No. 11,273,148 for AR101/Enzastaurin. This patent, titled "Targeted Epigenetic Therapy for Inherited Aortic Aneurism Condition," covers methods for the targeted epigenetic therapy of inherited aortic aneurysm and other diseases with altered regulation of TGFbeta genes, including Ehlers-Danlos Syndrome. This is the first issued patent supporting the portfolio and has an expiry date in August of 2038, assuming no patent term extensions.

ShowHide Related Items >><<
AYTU Aytu BioPharma
/

+

AYTU Aytu BioPharma
/

+

07/21/22 H.C. Wainwright
Aytu BioPharma price target lowered to $6 from $11 at H.C. Wainwright
05/17/22 Cantor Fitzgerald
Aytu BioPharma price target lowered to $5 from $11 at Cantor Fitzgerald
04/28/22 H.C. Wainwright
Aytu BioScience price target lowered to $11 from $24 at H.C. Wainwright
  • 09
    Aug
Syndicate
Aytu BioPharma 21.5M share Spot Secondary priced at 43c » 09:27
08/09/22
08/09
09:27
08/09/22
09:27
AYTU

Aytu BioPharma

/

+

Cantor Fitzgerald and…

Cantor Fitzgerald and Canaccord acted as joint book running managers for the offering.

ShowHide Related Items >><<
AYTU Aytu BioPharma
/

+

AYTU Aytu BioPharma
/

+

07/21/22 H.C. Wainwright
Aytu BioPharma price target lowered to $6 from $11 at H.C. Wainwright
05/17/22 Cantor Fitzgerald
Aytu BioPharma price target lowered to $5 from $11 at Cantor Fitzgerald
04/28/22 H.C. Wainwright
Aytu BioScience price target lowered to $11 from $24 at H.C. Wainwright
  • 09
    Aug
Hot Stocks
Aytu BioPharma announces pricing of public offering » 09:18
08/09/22
08/09
09:18
08/09/22
09:18
AYTU

Aytu BioPharma

/

+

Aytu BioPharma announced…

Aytu BioPharma announced the pricing of its underwritten public offering of 21,505,814 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 1,750,000 shares of its common stock, and (ii) accompanying warrants to purchase 23,255,814 shares of its common stock. The shares of common stockand the accompanying Common Warrants will be issued separately but can only be purchased together in this Offering. The combined public offering price for each share of common stock and accompanying Common Warrant is $0.43, and the combined offering price for each pre-funded warrant and accompanying Common Warrant is $0.429, which equals the public offering price per share of the common stock and accompanying Common Warrant, less the $0.001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds from the Offering are expected to be approximately $10 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Aytu. All of the securities in the Offering will be sold by Aytu. The Offering is expected to close on August 11, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the Offering for advancing the development of its pipeline assets, including for advancing the PREVEnt Trial evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome, for growth of the company's commercial business, and for working capital and general corporate purposes. Cantor and Canaccord Genuity are acting as the joint bookrunners for the Offering.

ShowHide Related Items >><<
AYTU Aytu BioPharma
/

+

AYTU Aytu BioPharma
/

+

07/21/22 H.C. Wainwright
Aytu BioPharma price target lowered to $6 from $11 at H.C. Wainwright
05/17/22 Cantor Fitzgerald
Aytu BioPharma price target lowered to $5 from $11 at Cantor Fitzgerald
04/28/22 H.C. Wainwright
Aytu BioScience price target lowered to $11 from $24 at H.C. Wainwright
  • 09
    Aug
Syndicate
Aytu BioPharma announces common stock, warrants offering » 17:05
08/08/22
08/08
17:05
08/08/22
17:05
AYTU

Aytu BioPharma

/

+

Aytu BioPharma announced…

Aytu BioPharma announced the launch of an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, and accompanying warrants to purchase its common stock. The company intends to use the net proceeds from the offering for advancing the development of its pipeline assets, including for advancing the PREVEnt Trial evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome (VEDS), for growth of the company's commercial business, and for working capital and general corporate purposes. Cantor and Canaccord Genuity are acting as the joint bookrunners for the offering.

ShowHide Related Items >><<
AYTU Aytu BioPharma
/

+

AYTU Aytu BioPharma
/

+

07/21/22 H.C. Wainwright
Aytu BioPharma price target lowered to $6 from $11 at H.C. Wainwright
05/17/22 Cantor Fitzgerald
Aytu BioPharma price target lowered to $5 from $11 at Cantor Fitzgerald
04/28/22 H.C. Wainwright
Aytu BioScience price target lowered to $11 from $24 at H.C. Wainwright
Recommendations
Aytu BioPharma price target lowered to $6 from $11 at H.C. Wainwright » 06:05
07/21/22
07/21
06:05
07/21/22
06:05
AYTU

Aytu BioPharma

/

+

H.C. Wainwright analyst…

H.C. Wainwright analyst Vernon Bernardino lowered the firm's price target on Aytu BioPharma to $6 from $11 and keeps a Buy rating on the shares. The analyst reduced the price target to reflect share dilution.

ShowHide Related Items >><<
AYTU Aytu BioPharma
/

+

AYTU Aytu BioPharma
/

+

05/17/22 Cantor Fitzgerald
Aytu BioPharma price target lowered to $5 from $11 at Cantor Fitzgerald
04/28/22 H.C. Wainwright
Aytu BioScience price target lowered to $11 from $24 at H.C. Wainwright
Hot Stocks
Aytu BioPharma initiates AR101 Phase 3 PREVEnt trial » 08:27
07/20/22
07/20
08:27
07/20/22
08:27
AYTU

Aytu BioPharma

/

+

Aytu BioPharma announced…

Aytu BioPharma announced the initiation of the global Phase 3 PREVEnt clinical trial of enzastaurin for the treatment of patients with COL3A1-positive Vascular Ehlers-Danlos Syndrome. VEDS is a rare genetic disorder typically diagnosed in childhood and characterized by arterial aneurysm, dissection and rupture, bowel rupture and rupture of the gravid uterus. The company has begun patient identification and study site contracting and has received regulatory clearance to initiate this registrational study in the United States and numerous countries in Europe. The PREVEnt Trial is a prospective, Phase 3, global, randomized, double-blind, placebo-controlled efficacy trial designed to evaluate enzastaurin in patients with genetically confirmed COL3A1-positive VEDS. The primary measure of the trial is to determine whether enzastaurin reduces the occurrence of VEDS-related arterial events requiring medical intervention compared to placebo. The company expects to enroll approximately 260 COL3A1-confirmed VEDS patients in the PREVEnt Trial.

ShowHide Related Items >><<
AYTU Aytu BioPharma
/

+

AYTU Aytu BioPharma
/

+

05/17/22 Cantor Fitzgerald
Aytu BioPharma price target lowered to $5 from $11 at Cantor Fitzgerald
04/28/22 H.C. Wainwright
Aytu BioScience price target lowered to $11 from $24 at H.C. Wainwright
Over a quarter ago
Syndicate
Aytu BioPharma files to sell 868K shares of common stock for holders  16:12
06/08/22
06/08
16:12
06/08/22
16:12
AYTU

Aytu BioPharma

/

+

 
ShowHide Related Items >><<
AYTU Aytu BioPharma
/

+

AYTU Aytu BioPharma
/

+

05/17/22 Cantor Fitzgerald
Aytu BioPharma price target lowered to $5 from $11 at Cantor Fitzgerald
04/28/22 H.C. Wainwright
Aytu BioScience price target lowered to $11 from $24 at H.C. Wainwright
Recommendations
Aytu BioPharma price target lowered to $5 from $11 at Cantor Fitzgerald » 07:55
05/17/22
05/17
07:55
05/17/22
07:55
AYTU

Aytu BioPharma

/

+

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Jennifer Kim lowered the firm's price target on Aytu BioPharma to $5 from $11 and keeps an Overweight rating on the shares. On Monday, Aytu BioPharma laid out three key strategic operational priorities that it will focus on in the near term: driving revenue growth with the Rx product franchise and consumer health products, enhancing financial performance through operational and manufacturing efficiencies and portfolio prioritization, and advancing and expanding the pipeline, and Kim believes that solid execution in CY23+ and upwards earnings-estimate revisions should drive shares higher, the analyst tells investors in a research note.

ShowHide Related Items >><<
AYTU Aytu BioPharma
/

+

AYTU Aytu BioPharma
/

+

04/28/22 H.C. Wainwright
Aytu BioScience price target lowered to $11 from $24 at H.C. Wainwright
Recommendations
Aytu BioScience price target lowered to $11 from $24 at H.C. Wainwright » 06:07
04/28/22
04/28
06:07
04/28/22
06:07
AYTU

Aytu BioPharma

/

+

H.C. Wainwright analyst…

H.C. Wainwright analyst Vernon Bernardino lowered the firm's price target on Aytu BioScience to $11 from $24 and keeps a Buy rating on the shares following the public offering. The analyst notes that his model does not include contribution from AR101, and thus, he views positive progress with AR101 as potential upside.

ShowHide Related Items >><<
AYTU Aytu BioPharma
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.